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Abstract
Liver metastases from adrenocortical carcinoma are very rare and no clear indications for surgery exist. The aim of the
present work was to define surgical indications for these neoplasms. All the patients submitted to hepatic resection for liver
metastases from adrenal carcinoma reported in the literature (PubMed source) from 1978 to 2005 were considered for the
present study. Forty-eight patients were found in the period of study, but it was only possible to obtain certain data for nine
patients (18.7%). The data investigated suggest that metachronous metastases, developed after a minimum of 1 year from
the primary tumor, and completely removable, may represent an indication for surgery / although this still needs to be
proved.
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Introduction
With an incidence of 0.5/2 cases per million popula-
tion each year, adrenocortical carcinoma represents a
very rare tumor [1]. Isolated liver metastases are even
more rare, since only about 50 cases have been
reported in the literature. The majority of these cases
have been comprehensively discussed in association
with other noncolorectal nonneuroendocrine liver
metastases.
The aim of this study was to analyze exclusively
liver metastases from adrenal carcinoma in order to
determine indications for surgery.
Patients and methods
All the patients submitted to hepatic resection for liver
metastases from adrenal carcinoma reported in litera-
ture (PubMed source) from 1978 to 2005 were
considered for the present study. The following details
were considered for each publication: the number of
patients, sex, age, time of metastases presentation in
relation to primary tumor, number of metastases, size
of the tumor, localization in the liver, extent of
resection (according to Couinaud [2] classification
of minor hepatic resection is defined as less than two
segments, major hepatic resection as three or more
segments), adjuvant chemotherapeutic treatment, dis-
ease-free interval (DFI), survival after liver resection
and outcome. Literature with incomplete data was
investigated by an e-mail request addressed to the
authors of the original reports.
Results
Patients considered for this study are listed in Table I
[3/15]. Forty-eight patients were found in the period
of study, but it was only possible to obtain certain data
for nine patients (18.7%).
A case of a female patient aged 36 years, affected by
adrenal carcinoma and developing a single liver
metastasis 3 years after primary tumor resection, has
been reported by our group [13]. The lesion was
located in segment 6 of the liver and a segmentectomy
was performed. The patient is alive without any
relapse. No chemotherapy has been administered.
Williams et al. reported the case of a male patient
submitted to a two-stage subtotal hepatectomy 20
months after an adrenalectomy for bilobar liver
metastases [12]. A metastasis of 9 cm in diameter
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Table I. Liver metastases from adrenocortical carcinoma reported in the literature*.
References Year
Number of
patients Sex Age (years)
Time from primary
tumor
Number of
metastases Site Size (cm)
Extension of
resection Chemotherapy DFI Survival Outcome
Foster [3] 1978 2 / / / / / / / / / / /
Cobourn et al. [4] 1987 2 / / / / / / / / / / /
Iwatsuki & Starzl [5] 1988 4 / / / / / / / / / / /
Harrison et al. [6] 1997 7 / / / / / / / / / /
Berney et al. [7] 1998 1 Female 27 Met (36 months) 2 Segment 4 2.8/6 Minor Yes (mitotane) 135 months 135 months Alive
Lang et al. [8] 1999 6 / / / / / / / / / / /
Hemming et al. [9] 2000 3 / / / / / / / / / / /
Laurent et al. [10] 2001 1 / / Met (22 months) / Bilobar / / / / 42 months Dead
Langer et al. [11] 2000 2 / / Syn 1 / / Minor / / 1 months Dead
/ / / / / Met 1 / / Minor / / 4 months Dead
Williams et al. [12] 2002 1 / / Met (20 months) 3 Bilobar 9, 7, 5,
respectively
Major No 18 months 27 months Dead
Di Carlo et al. [13] 2004 1 Female 32 Met (36 months) 1 Segment 6 7 Minor No 38 months 38 months Alive
Weitz et al. [14] 2005 15 / / / / / / / / / / /
Ercolani et al. [15] 2005 3 Male 18 Syn 4 / 12 / / / 11 months Dead
/ / / Male 22 Met (6 months) 6 Right lobe 7 Major No 6 months 10 months Dead
/ / / Male 51 Syn 3 / 5 / / / 6 months Dead
Total number of
patients
48
syn, synchronous; met, metachronous; DFI, disease-free interval.
*Search of PubMed.
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was located in the left lobe, and two lesions, measur-
ing 7 and 5 cm, respectively, in the right lobe. A right
hemihepatectomy and cryotherapy to the left lobe
were performed at the first step; 4 months later the
patient was submitted to a left lobectomy including
the mass treated with cryotherapy. The patient was
free from disease for 18 months, but he died 2 years
and 3 months after the initial liver resection. The
cause of death is not specified in the manuscript.
Langer et al. report the cases of two patients
affected by hepatic metastases from adrenal carci-
noma [11]. In one patient the metastasis was syn-
chronous, so adrenalectomy, nephrectomy and
resection of liver metastasis were performed at the
same time. This patient died 1 month after surgical
treatment. The second patient, after resection of
primary tumor, developed a local recurrence and liver
metastasis that were both resected, but the patient
survived only 4 months. The single case reported by
Berney et al. [7] has experienced an excellent survival
of 135 months. In contrast, the patients in the report
by Ercolani et al. had a poor outcome [15]. These
patients were affected by synchronous metastases or
had a limited DFI between the primary tumor and the
liver metastases.
The remaining patients presented in the literature
are reported comprehensively with other kinds of
tumor, and data are incomplete.
Discussion
Adrenal carcinoma is a rare malignancy with a poor
prognosis. Different reports have been published with
different conclusions about the appropriate treatment
of this tumor. However, the basis of any treatment is
the complete surgical ablation of the tumor and of the
local or metastatic recurrence. Hepatic metastases
from adrenal carcinoma are very rare and concern the
field of noncolorectal nonneuroendocrine metastases.
The presented data are limited and details of only a
few of these cases are complete. We have contacted
the authors of the recent reports but, due to moving to
other hospitals and consequent lack of access to the
old data [8], or no reply to our requests [6,9], some
reported cases remain incomplete. Of the data re-
ported in the present study the best results were
achieved in patients with metachronous metastases
developed after a disease-free survival /1 year in
which a complete resection was performed. The
patients with synchronous metastases had poor re-
sults, recurrence occurred rapidly and the survival was
short.
Surgery is the only choice of treatment for meta-
static disease, because there is no definitive protocol
for chemotherapy, and although therapy with mito-
tane is commonly used, its therapeutic value, alone or
in combination with other chemotherapeutic agents,
is still very controversial. In fact, the use of mitotane
after surgical resection, as recommended by some
authors, to improve the survival, has not been proved
to be effective [1,16]. Cryotherapy has been reported
as a bridging therapy to prevent progression of the
remaining tumor, in order to perform a two-stage
subtotal hepatectomy for multiple metastases from
adrenal carcinoma [12].
In conclusion, no guidelines can be given, but this
study suggests that metachronous metastases, devel-
oped after a minimum of 1 year from the primary
tumor, and completely removable, may represent an
indication for surgery, although this has still to be
proved. Cryotherapy or radiofrequency ablation can
be used to make the metastases resectable.
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